Lifecore Biomedical, Inc. (LFCR) vs Lexeo Therapeutics, Inc. Common Stock (LXEO)
Over the past year, LXEO lagged LFCR — -48.33% vs -6.56% annualized total return (price plus dividends).
A side-by-side comparison of Lifecore Biomedical, Inc. and Lexeo Therapeutics, Inc. Common Stock across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
Total return — LFCR vs LXEO
growth of $100 · dividends reinvested · last 3yMetrics side by side
Did LXEO beat LFCR?
Over the past year, LXEO lagged LFCR — -48.33% vs -6.56% annualized total return (price plus dividends).
Total return (annualized)
| Metric | LFCR | LXEO |
|---|---|---|
| Total return (1Y) | -6.56% | -48.33% |
| Total return CAGR (3Y) | -1.05% | N/A |
| Total return CAGR (5Y) | -7.12% | N/A |
| Total return CAGR (10Y) | -6.99% | N/A |
LFCR is an index fund, so valuation, profitability, and per-company growth metrics don't apply — the head-to-head here is total return (price plus reinvested dividends).
Frequently asked
- Has LXEO beaten LFCR?
- Over the past year, LXEO lagged LFCR — -48.33% vs -6.56% annualized total return (price plus dividends).
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.